A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab

• Main Authors: Andrew McKenzie (Author), Anthony Roberts (Author), Sourabh Malandkar (Author), Henrike Feuersenger (Author), Con Panousis (Author), Dipti Pawaskar (Author)
• Format: Book
• Published: Wiley, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Factor XII (FXII) is the principal initiator of the plasma contact system and has proinflammatory and prothrombotic activities. This single‐center, first‐in‐human phase I study aimed to assess the safety and tolerability of single escalating doses of garadacimab, a monoclonal antibody that...